This technology is a technique to treat individuals experiencing subfertility using a capsid-based drug delivery system.
Current methods to treat subfertility involve the use of assisted reproductive technology (ART) which is often invasive, expensive, and involves varying success rates. Additionally, ART is not a successful approach to treat subfertility due to maternal age. A potential alternative to such treatments is using endogenous factors to promote fertility through a less invasive and more natural approach. However, there are currently no platforms that can promote fertility in this way.
This technology describes capsid-like structures that contain molecular cargo and can be released from reproductive tissues like ovaries and testes. These capsid structures are stable outside of the cell for over a month when stored properly and can be purified from bioengineered cell lines or mammalian tissues to then be administered non-invasively. Thus, this technology describes a less expensive and invasive drug delivery system for both men and women experiencing subfertility influenced by a range of factors, including advanced maternal age.
Patent Pending
IR CU23365
Licensing Contact: Jerry Kokoshka